1 / 8

Thailand 23 - 27 Jul 2012

Function 2: Pharmacovigilance Activities including Surveillance of Adverse Events Following Immunization (AEFI). Thailand 23 - 27 Jul 2012. PMS function assessor team. Dr. Ananda Amarasinghe Consultant Epidemiologist EPI Unit MOH Colombo Sri-Lanka

gaston
Download Presentation

Thailand 23 - 27 Jul 2012

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Function 2: Pharmacovigilance Activities including Surveillance of Adverse Events Following Immunization (AEFI) Thailand 23 - 27 Jul 2012

  2. PMS function assessor team Dr. Ananda Amarasinghe Consultant Epidemiologist EPI Unit MOH Colombo Sri-Lanka Dr. Ajay Kera, Deputy Commissioner, Ministry of Health & Family Welfare New Delhi, India Dr. Dina Pfeifer, Regional Advisor EPI, WHO regional Office for Europe Mr. Stephane Guichard, Vaccine Supply and Quality, Immunization and Vaccine Development, WHO regional Office for South East Asia

  3. Place and institutions visited Team 1: Visited Khon Kaen Dr. Ajay Khera, Dr. Dina Pfeifer, Dr. Darin Areechokchai BOE/MOPH, Ms Papaiji Suangtho BOE/MOPH, Mr. Padejsak Chobdham Bureau general Communicable Department. Team 2: Visited Angthong province Dr. Ananda Amarasinghe, Mr. Stephane Guichard, Mrs Kanoktip Thiparat BOE/MOPH and Mrs Porpit Barinsathien MOPH.

  4. Function 2: Pharmacovigilance Activities including Surveillance of Adverse Events Following Immunization (AEFI)Function status

  5. Pharmacovigilance Activities including Surveillance of Adverse Events Following Immunization (AEFI) Indicators results

  6. Strengths The system has significantly improved since the last NRA assessment in 2008. PMS system well established system AEFI are notifiable under the national disease surveillance system Expertise available at central, provincial and regional levels The country has a good investigation capacity to address vaccine safety and performance. Regular meetings at provincial and regional levels are conducted to review and analyze AEFI reports with good interactions with central level which review all cases. Information feedback is provided through the MOPH internet and periodic reports are prepared by BOE/AEFI. The system capture serious and non-serious AEFI throughout the National Immunization program Regular training of staff at every levels.

  7. Areas for improvement QMS implemented in NRA but not fully extended to BOE to cover detection, reporting and detailed analysis including feed back. Analysis methodology e.g.: analysis by rates, by dose of vaccines, by product,… To address under-reporting there are needs to standardized selected non-serious AEFI by applying simplified Brighton case definition. Further improvement of the system requires increased HR capacity at central level. Need to be more actively engaged in international/regional PMS activities to foster capacity building and keep abreast of latest regulatory requirements. E.g participation in NRA assessment, facilitating training organized by WHO in other countries

  8. Khob Kun Khab !

More Related